DeciBio Consulting LLC Launches EU-5 Oncology Genomics Tracker, Revealing Adoption Trends and Precision Medicine Gaps

A new survey-based Genomics Tracker focused on the EU-5 (France, Germany, Italy, Spain, and the United Kingdom) by DeciBio Consulting LLC provides update...

February 18, 2026 | Wednesday | Reports
Sapu Bioscience Secures Global IP Fortress for OT-101, Advancing Integrated CNS Platform in Neurology and Oncology

Sapu Bioscience announced advancements in its global IP portfolio supporting OT-101, its proprietary TGF-β antisense therapeutic platform, stre...

February 18, 2026 | Wednesday | News
QuidelOrtho Strengthens Global Immunoassay Portfolio Through Strategic Agreement With Lifotronic Technology

QuidelOrtho has entered a long-term strategic supply agreement with Lifotronic Technology Co., Ltd. (Lifotronic Technology Co., Ltd., stock code: 68838...

February 17, 2026 | Tuesday | News
MEDIPOST Inc. Files IND Amendment to Advance Phase III Stem Cell Therapy Trial for Knee Osteoarthritis

MEDIPOST Inc., a biotechnology company developing allogeneic, umbilical cord blood-derived stem cell therapies for inflammation-driven degenerative disea...

February 16, 2026 | Monday | News
Valar Labs Expands AI Oncology Platform with Vitara Pancreas ChemoPredict Validation

New AI diagnostic, Vitara Pancreas ChemoPredict, can select optimal first-line treatment for advanced pancreatic cancer patients. Valar Labs, ...

February 13, 2026 | Friday | News
Ferronova Completes Patient Enrolment in Pivotal Trial of FerroTrace Surgical Imaging Technology

Australian company Ferronova announced it has completed enrolment of patients for its two-year trial to progress commercialisation of FerroTrace, a ...

February 11, 2026 | Wednesday | News
Bayer’s Asundexian Reduces Recurrent Stroke Risk by 26 Percent in Landmark Phase III Trial

In OCEANIC-STROKE, patients who received asundexian after a non-cardioembolic ischemic stroke or high-risk transient ischemic attack were significant...

February 10, 2026 | Tuesday | News
Median Technologies Secures FDA Clearance for AI Powered eyonis LCS Lung Cancer Screening Software

eyonis® LCS aims to redefine lung cancer screening by supporting diagnosis at early, curable stages, while reducing false positives to avoid unne...

February 10, 2026 | Tuesday | News
Geneoscopy Strengthens Diagnostic Market Position After USPTO Invalidates Exact Sciences Patent Claims

Decision removes last patent hurdle as Geneoscopy advances ColoSense®, its RNA-based noninvasive colorectal cancer screening test Geneosco...

February 09, 2026 | Monday | News
Ascentage Pharma Strengthens Hematologic Cancer Pipeline with Global Clinical Advancement of APG-3288

Ascentage Pharma Group International , a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commerc...

February 09, 2026 | Monday | News
Aminex Launches Mid-Stage Trial of Polyamine-Targeting Therapy in Solid Tumors

Novel approach attacks production of polyamines that tumors require to proliferate and suppress the immune system  Aminex Therapeutics, Inc., a...

February 06, 2026 | Friday | News
10x Genomics Powers UK PharosAI Initiative to Build Multimodal Cancer Dataset

Initiative will create one of the world's largest multimodal cancer datasets and an integrated suite of AI models and tools to fuel p...

February 06, 2026 | Friday | News
Pfizer CEO Albert Bourla Signals Confidence in 2026 as Company Delivers Solid 2025 Results

Dr. Albert Bourla, Chairman and CEO of Pfizer, said: “With excellent execution in 2025, we delivered a solid financial performance and strengt...

February 05, 2026 | Thursday | Company results
Ernexa Therapeutics Selected for Japan Entry Acceleration Program, Joining Elite Group of Global Cell Therapy Innovators

Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, to...

January 29, 2026 | Thursday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2026 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close